# Efficacy and Safety Evaluating Study to Compare Uritos® (Imidafenacin) and Urotol® (Tolterodine) for Treatment of Overactive Bladder.

> **NCT03575702** · PHASE3 · COMPLETED · sponsor: **R-Pharm** · enrollment: 300 (actual)

## Conditions studied

- Overactive Bladder

## Interventions

- **DRUG:** Uritos®
- **DRUG:** Urotol®

## Key facts

- **NCT ID:** NCT03575702
- **Lead sponsor:** R-Pharm
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-07-18
- **Primary completion:** 2017-08-01
- **Final completion:** 2017-09-01
- **Target enrollment:** 300 (ACTUAL)
- **Last updated:** 2019-05-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03575702

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03575702, "Efficacy and Safety Evaluating Study to Compare Uritos® (Imidafenacin) and Urotol® (Tolterodine) for Treatment of Overactive Bladder.". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03575702. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*